Warde Medical Laboratory

LABORATORY REPORT

QC ACCOUNT (WARDE)
300 W. TEXTILE
ANN ARBOR MI 48108

EXAMPLE, REPORT W
WX0000003827 M 07/08/1968 56 Y

Referral Testing

Collected: 03/11/2025 08:05 Received: 03/11/2025 08:05

Test Name	Result	Flag	Ref-Ranges	Units	Site
Antimicrobial Susceptibility, AFB/Mycobacteria					
Organism ID	Mycobacterium intracellulare				WMAR
Antimicrobial Susceptibility, AFB/Mycobacteria	See Below				WMAR

```
Test Requested
Antimicrobial Susceptibility, AFB/Mycobacteria

Source: Respiratory
Body Site: Sputum
Free Text Sources: Resp

Final Report

Mycobacterium intracellulare
Organism identified by client

Susceptibility Results

Organism: Mycobacterium intracellulare

Amikacin                  Interpretation: SUSCEPTIBLE
                          MIC (ug/mL): 4
Clarithromycin            Interpretation: SUSCEPTIBLE
                          MIC (ug/mL): 0.25
Linezolid                 Interpretation: SUSCEPTIBLE
                          MIC (ug/mL): 8
Moxifloxacin              Interpretation: SUSCEPTIBLE
                          MIC (ug/mL): 1

Interpretive Information  Interpretation: SEE NOTE

For Mycobacterium avium-intracellulare complex, CLSI
recommends testing and reporting clarithromycin,
moxifloxacin, amikacin and linezolid. The reported amikacin
interpretation is for IV; if using amikacin (liposomal,
inhaled), the MIC interpretive breakpoints are <=64 ug/mL
Susceptible, >=128 ug/mL Resistant. The in vivo
effectiveness of Moxifloxacin and Linezolid for MAC disease
is unproven. Ethambutol, rifampin and rifabutin MIC results
are not reported because MIC values are not predictive of
clinical responses and may be misleading.

Susceptibility performed by a non-standardized methodology.
Interpret results in conjunction with clinical presentation.
Test developed and characteristics determined by ARUP
```

QC ACCOUNT (WARDE)
300 W. TEXTILE
ANN ARBOR MI 48108

EXAMPLE, REPORT W
WX0000003827 M 07/08/1968 56 Y

Referral Testing

Collected: 03/11/2025 08:05 Received: 03/11/2025 08:05

Test Name	Result	Flag	Ref-Ranges	Units	Site

Laboratories. See compliance Statement B: aruplab.com/CS.

Interpretive Results
INTERPRETIVE INFORMATION: Susceptibility, Mycobacteria

Units = ug/mL

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Performed by ARUP Laboratories
500 Chipeta Way, Salt Lake City, UT 84108
Jonathan R. Genzen, MD, PhD, Laboratory Director

Reported Date: 03/11/2025 08:12 ASAFB

Performing Site:
WMAR: ARUP LABORATORIES 500 Chipeta Way Salt Lake City UT 841081221